% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Merz:127122,
      author       = {M. Merz$^*$ and H. Salwender and M. Haenel and E. K. Mai
                      and U. Bertsch and C. Kunz$^*$ and T. Hielscher$^*$ and I.
                      W. Blau and C. Scheid and D. Hose and A. Seckinger and A.
                      Jauch and J. Hillengass$^*$ and M.-S. Raab$^*$ and B.
                      Schurich and M. Munder and I. G. H. Schmidt-Wolf and C.
                      Gerecke and H.-W. Lindemann and M. Zeis and K. Weisel and J.
                      Duerig and H. Goldschmidt},
      title        = {{S}ubcutaneous versus intravenous bortezomib in two
                      different induction therapies for newly diagnosed multiple
                      myeloma: an interim analysis from the prospective
                      {GMMG}-{MM}5 trial.},
      journal      = {Haematologica},
      volume       = {100},
      number       = {7},
      issn         = {1592-8721},
      address      = {Pavia},
      publisher    = {Ferrata Storti Foundation},
      reportid     = {DKFZ-2017-03148},
      pages        = {964 - 969},
      year         = {2015},
      abstract     = {We investigated the impact of subcutaneous versus
                      intravenous bortezomib in the MM5 trial of the
                      German-Speaking Myeloma Multicenter Group which compared
                      bortezomib, doxorubicin, and dexamethasone with bortezomib,
                      cyclophosphamide, and dexamethasone induction therapy in
                      newly diagnosed multiple myeloma. Based on data from
                      relapsed myeloma, the route of administration for bortezomib
                      was changed from intravenous to subcutaneous after 314 of
                      604 patients had been enrolled. We analyzed 598 patients who
                      received at least one dose of trial medication. Adverse
                      events were reported more frequently in patients treated
                      with intravenous bortezomib $(intravenous=65\%;$
                      $subcutaneous=56\%,$ P=0.02). Rates of grade 2 or more
                      peripheral neuropathy were higher in patients treated with
                      intravenous bortezomib during the third cycle
                      $(intravenous=8\%;$ $subcutaneous=2\%,$ P=0.001). Overall
                      response rates were similar in patients treated
                      intravenously or subcutaneously. The presence of
                      International Staging System stage III disease, renal
                      impairment or adverse cytogenetic abnormalities did not have
                      a negative impact on overall response rates in either group.
                      To our knowledge this is the largest study to present data
                      comparing subcutaneous with intravenous bortezomib in newly
                      diagnosed myeloma. We show better tolerance and similar
                      overall response rates for subcutaneous compared to
                      intravenous bortezomib. The clinical trial is registered at
                      eudract.ema.europa.eu as n. 2010-019173-16.},
      keywords     = {Antineoplastic Agents (NLM Chemicals) / Bortezomib (NLM
                      Chemicals) / Dexamethasone (NLM Chemicals) / Doxorubicin
                      (NLM Chemicals) / Cyclophosphamide (NLM Chemicals)},
      cin          = {E010 / C060 / G330 / G170},
      ddc          = {610},
      cid          = {I:(DE-He78)E010-20160331 / I:(DE-He78)C060-20160331 /
                      I:(DE-He78)G330-20160331 / I:(DE-He78)G170-20160331},
      pnm          = {315 - Imaging and radiooncology (POF3-315)},
      pid          = {G:(DE-HGF)POF3-315},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:25840597},
      pmc          = {pmc:PMC4486231},
      doi          = {10.3324/haematol.2015.124347},
      url          = {https://inrepo02.dkfz.de/record/127122},
}